<SEC-DOCUMENT>0001513162-21-000090.txt : 20210625
<SEC-HEADER>0001513162-21-000090.hdr.sgml : 20210625
<ACCEPTANCE-DATETIME>20210624194734
ACCESSION NUMBER:		0001513162-21-000090
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210624
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210625
DATE AS OF CHANGE:		20210624

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOMERICA INC
		CENTRAL INDEX KEY:			0000073290
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				952645573
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0531

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37863
		FILM NUMBER:		211044274

	BUSINESS ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614
		BUSINESS PHONE:		9496452111

	MAIL ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NMS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19871130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR MEDICAL SYSTEMS INC
		DATE OF NAME CHANGE:	19830216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR INSTRUMENTS INC
		DATE OF NAME CHANGE:	19720508
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<head><title>Form 8-K</title> </head> <body style=WORD-WRAP:break-word lang=EN-GB> <div style=page:WordSection1> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font lang=EN-US>UNITED STATES</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font lang=EN-US>SECURITIES AND EXCHANGE COMMISSION</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font lang=EN-US>WASHINGTON, D.C.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font lang=EN-US>FORM 8-K</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font lang=EN-US>CURRENT REPORT</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US>Pursuant to Section 13 or 15(d) of the</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US>Securities Exchange Act of 1934</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US>Date of Report (date of earliest event reported): <b>June 24, 2021</b></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><u><font lang=EN-US>BIOMERICA, INC.</font></u></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US>(Exact Name of Registrant as Specified in its Charter)</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <div align=center> <table width=696 bordercolor=transparent style="WIDTH:522pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:13pt> <td width=232 style="BORDER-TOP:0px; HEIGHT:13pt; BORDER-RIGHT:0px; WIDTH:174pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; BORDER-LEFT:0px; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:2pt 0cm' align=center><a name=Form_8_K><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>Delaware</font></a></p></td> <td width=232 style="BORDER-TOP:0px; HEIGHT:13pt; BORDER-RIGHT:0px; WIDTH:174pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; BORDER-LEFT:0px; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:2pt 0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>001-37863</font></p></td> <td width=232 style="BORDER-TOP:0px; HEIGHT:13pt; BORDER-RIGHT:0px; WIDTH:174pt; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; BORDER-LEFT:0px; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:2pt 0cm' align=center><font style="FONT-SIZE:10pt; COLOR:black" lang=EN-US>95-2645573</font></p></td></tr> <tr style=HEIGHT:26pt> <td width=232 style="HEIGHT:26pt; WIDTH:174pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:2pt 0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>(State or Other <br>Jurisdiction of <br>Incorporation)</font></p></td> <td width=232 style="HEIGHT:26pt; WIDTH:174pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:2pt 0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>(Commission</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:2pt 0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>File Number)</font></p></td> <td width=232 style="HEIGHT:26pt; WIDTH:174pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:2pt 0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>(IRS Employer</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:2pt 0cm' align=center><font style=FONT-SIZE:10pt lang=EN-US>Identification No.)</font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US>17571 Von Karman Ave.</font></p> <h1 style='FONT-SIZE:12pt; TEXT-DECORATION:underline; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-AFTER:none; FONT-WEIGHT:normal; TEXT-ALIGN:center; MARGIN:0cm'><font lang=EN-US>Irvine, California 92614</font></h1> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US>(Address of Principal Executive Offices</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US>Including Zip Code)</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><u><font lang=EN-US></font></u>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><u><font lang=EN-US>949-645-2111</font></u></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US>(Registrant&#146;s Telephone Number,</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US>Including Area Code)</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><b><font lang=EN-US>Not applicable</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><u><font lang=EN-US></font></u>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US>(Former Name or Former Address if Changed</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US>Since Last Report)</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font lang=EN-US>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:12pt 0cm 0cm'><font style="FONT-SIZE:11pt; FONT-FAMILY:Wingdings; COLOR:black">o</font><font lang=EN-US>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>&nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:11pt; FONT-FAMILY:Wingdings; COLOR:black">o</font><font lang=EN-US>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>&nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:11pt; FONT-FAMILY:Wingdings; COLOR:black">o</font><font lang=EN-US>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<br>&nbsp;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:11pt; FONT-FAMILY:Wingdings; COLOR:black">o</font><font lang=EN-US>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm; LINE-HEIGHT:120%'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:3pt 0cm 0cm; LINE-HEIGHT:120%'><font lang=EN-US>Securities registered pursuant to Section 12(b) of the Act:<br>&nbsp;</font></p> <div align=center> <table width=683 bordercolor=transparent style="WIDTH:512pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr style=HEIGHT:14pt> <td width=235 style="HEIGHT:14pt; WIDTH:176pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-AFTER:none; TEXT-ALIGN:center; MARGIN:2pt 0cm' align=center><b><u><font style="FONT-SIZE:9pt; COLOR:black" lang=EN-US>Title of each class</font></u></b></p></td> <td width=92 style="HEIGHT:14pt; WIDTH:69pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-AFTER:none; TEXT-ALIGN:center; MARGIN:2pt 0cm' align=center><b><u><font style="FONT-SIZE:9pt; COLOR:black" lang=EN-US>Trading Symbol</font></u></b></p></td> <td width=356 style="HEIGHT:14pt; WIDTH:267pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-AFTER:none; TEXT-ALIGN:center; MARGIN:2pt 0cm' align=center><b><u><font style="FONT-SIZE:9pt; COLOR:black" lang=EN-US>Name of each exchange on which registered</font></u></b></p></td></tr> <tr style=HEIGHT:14pt> <td width=235 style="HEIGHT:14pt; WIDTH:176pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-AFTER:none; TEXT-ALIGN:center; MARGIN:2pt 0cm' align=center><font style="FONT-SIZE:9pt; COLOR:black" lang=EN-US>Common Stock, par value $0.08</font></p></td> <td width=92 style="HEIGHT:14pt; WIDTH:69pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-AFTER:none; TEXT-ALIGN:center; MARGIN:2pt 0cm' align=center><font style="FONT-SIZE:9pt; COLOR:black" lang=EN-US>BMRA</font></p></td> <td width=356 style="HEIGHT:14pt; WIDTH:267pt; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:3pt; PADDING-RIGHT:3pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-AFTER:none; TEXT-ALIGN:center; MARGIN:2pt 0cm' align=center><font style="FONT-SIZE:9pt; COLOR:black" lang=EN-US>NASDAQ Capital Market</font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm -10pt 0cm 0cm; LINE-HEIGHT:120%'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm -10pt 0cm 0cm; LINE-HEIGHT:120%'><font lang=EN-US>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).&nbsp;&nbsp; Emerging growth company&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style=FONT-FAMILY:Wingdings lang=EN-US>&#168;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:12pt -10pt 0pt 0cm; LINE-HEIGHT:120%'><font lang=EN-US>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp; </font><font style=FONT-FAMILY:Wingdings lang=EN-US>&#168;</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US>1</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b></b>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><b><font lang=EN-US>Item 7.01 Regulation FD Disclosures.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN-LEFT:0cm; MARGIN-RIGHT:2.9pt'><font lang=EN-US>On June 24, 2021, Biomerica, Inc. (&#147;Biomerica&#148;) issued a press release announcing that the Company has signed an exclusive five-year distribution agreement with a Canadian partner for the distribution and marketing of Biomerica&#146;s new and proprietary Helicobacter pylori test.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN-LEFT:0cm; MARGIN-RIGHT:2.9pt'><font lang=EN-US>A copy of Biomerica&#146;s press release is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated in this Item 7.01 in its entirety.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font lang=EN-US>The information contained in Item 7.01 of this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be &#147;filed&#148; for purposes of Section 18 of, or otherwise regarded as filed under, the&nbsp;Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the&nbsp;Securities Act of 1933, as amended, or the&nbsp;Exchange Act, except as shall be expressly set forth by specific reference in such filing.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><b><font lang=EN-US>Item 8.01&nbsp; Other Events.</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'><font lang=EN-US>On June 21, 2021, the Company signed the exclusive distribution and marketing agreement in Canada for its Helicobacter pylori test.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif;  TEXT-ALIGN:justify; MARGIN:0cm'><b><font style=COLOR:black lang=EN-US>Item&nbsp;9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Financial Statements and Exhibits</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 0cm 0cm 36pt; TEXT-INDENT:-18pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:36pt'><font lang=EN-US>(d) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exhibits.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm; TEXT-INDENT:36pt'>&nbsp;</p> <table width=733 bordercolor=transparent style="WIDTH:550pt; BORDER-COLLAPSE:collapse" cellpadding=0 cellspacing=0> <tr> <td width=9% nowrap style="BORDER-TOP:0px; BORDER-RIGHT:0px; WIDTH:9.26%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0.7pt; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0.7pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-AFTER:none; TEXT-ALIGN:center; MARGIN:0cm; LINE-HEIGHT:115%' align=center><font style="FONT-SIZE:10pt; LINE-HEIGHT:115%" lang=EN-US>&nbsp;</font><b><font style="FONT-SIZE:10pt; LINE-HEIGHT:115%" lang=EN-US>Number</font></b></p></td> <td width=1% style="WIDTH:1.08%; PADDING-BOTTOM:0cm; PADDING-TOP:0.7pt; PADDING-LEFT:0cm; PADDING-RIGHT:0.7pt" valign=bottom> <p style='FONT-SIZE:4pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm; LINE-HEIGHT:115%'><font style="FONT-SIZE:10pt; LINE-HEIGHT:115%" lang=EN-US>&nbsp;&nbsp;</font></p></td> <td width=89% nowrap style="BORDER-TOP:0px; BORDER-RIGHT:0px; WIDTH:89.66%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0.7pt; BORDER-LEFT:0px; PADDING-RIGHT:0.7pt" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-AFTER:none; MARGIN:0cm; LINE-HEIGHT:115%'><b><font style="FONT-SIZE:10pt; LINE-HEIGHT:115%" lang=EN-US>Description</font></b></p></td></tr> <tr> <td width=9% style="BORDER-TOP:0px; BORDER-RIGHT:0px; WIDTH:9.26%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0.7pt; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0.7pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm; LINE-HEIGHT:115%'>&nbsp;</p></td> <td width=1% style="WIDTH:1.08%; PADDING-BOTTOM:0cm; PADDING-TOP:0.7pt; PADDING-LEFT:0cm; PADDING-RIGHT:0.7pt" valign=bottom> <p style='FONT-SIZE:4pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm; LINE-HEIGHT:115%'>&nbsp;</p></td> <td width=89% style="BORDER-TOP:0px; BORDER-RIGHT:0px; WIDTH:89.66%; BORDER-BOTTOM:0px; PADDING-BOTTOM:0cm; PADDING-TOP:0.7pt; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0.7pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm; LINE-HEIGHT:115%'>&nbsp;</p></td></tr> <tr> <td width=9% style="WIDTH:9.26%; PADDING-BOTTOM:0cm; PADDING-TOP:0.7pt; PADDING-LEFT:0cm; PADDING-RIGHT:0.7pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm; LINE-HEIGHT:115%'><font lang=EN-US>99.1</font></p></td> <td width=1% style="WIDTH:1.08%; PADDING-BOTTOM:0cm; PADDING-TOP:0.7pt; PADDING-LEFT:0cm; PADDING-RIGHT:0.7pt" valign=bottom> <p style='FONT-SIZE:4pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm; LINE-HEIGHT:115%'>&nbsp;</p></td> <td width=89% style="WIDTH:89.66%; PADDING-BOTTOM:0cm; PADDING-TOP:0.7pt; PADDING-LEFT:0cm; PADDING-RIGHT:0.7pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm -5.65pt 0cm 0cm; LINE-HEIGHT:115%'><font lang=EN-US>Press Release issued June 24, 2021.</font></p></td></tr></table> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US>2</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US> <hr> <DIV style="PAGE-BREAK-BEFORE: always"></DIV> </font></div> <h2 style='FONT-SIZE:12pt; TEXT-DECORATION:underline; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-AFTER:none; FONT-WEIGHT:normal; TEXT-ALIGN:left; MARGIN:0cm 21.6pt 0cm 0cm' align=left><font lang=EN-US></font>&nbsp;</h2> <h2 style='FONT-SIZE:12pt; TEXT-DECORATION:underline; FONT-FAMILY:"Times New Roman",serif; PAGE-BREAK-AFTER:none; FONT-WEIGHT:normal; TEXT-ALIGN:center; MARGIN:0cm 21.6pt 0cm 0cm'><font lang=EN-US>SIGNATURE</font></h2> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm 21.6pt 0cm 0cm'><u><font lang=EN-US></font></u>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 21.6pt 0cm 0cm'><font lang=EN-US>&nbsp;&nbsp;&nbsp;&nbsp; Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:justify; MARGIN:0cm 21.6pt 0cm 0cm'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm 21.6pt 0cm 0cm' align=center><u><font lang=EN-US></font></u>&nbsp;</p> <table width=600 bordercolor=transparent style="WIDTH:450pt; BORDER-COLLAPSE:collapse; MARGIN-LEFT:-0.75pt" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=50% nowrap style="HEIGHT:15pt; WIDTH:50%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><a name=T13><font style="FONT-SIZE:11pt; COLOR:black" lang=EN-US>Dated:&nbsp; June 25, 2021</font></a></p></td> <td width=47% colspan=2 nowrap style="HEIGHT:15pt; WIDTH:47%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:11pt; COLOR:black" lang=EN-US>Biomerica, Inc.</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=50% nowrap style="HEIGHT:15pt; WIDTH:50%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=47% nowrap style="HEIGHT:15pt; WIDTH:47%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /></tr> <tr style=HEIGHT:15pt> <td width=50% nowrap style="HEIGHT:15pt; WIDTH:50%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:11pt; COLOR:black" lang=EN-US>By:</font></p></td> <td width=47% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:47%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; BORDER-LEFT:0px; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:11pt; COLOR:black" lang=EN-US>/s/&nbsp;Zackary S. Irani</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=50% nowrap style="HEIGHT:15pt; WIDTH:50%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=47% nowrap style="HEIGHT:15pt; WIDTH:47%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:11pt; COLOR:black" lang=EN-US>Zackary S. Irani</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=50% nowrap style="HEIGHT:15pt; WIDTH:50%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom /> <td width=47% nowrap style="HEIGHT:15pt; WIDTH:47%; PADDING-BOTTOM:0cm; PADDING-TOP:0cm; PADDING-LEFT:0cm; PADDING-RIGHT:0cm" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; MARGIN:0cm'><font style="FONT-SIZE:11pt; COLOR:black" lang=EN-US>Chief Executive Officer</font></p></td></tr></table> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm 21.6pt 0cm 0cm' align=center><u><font lang=EN-US></font></u>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; TEXT-ALIGN:center; MARGIN:0cm' align=center><font lang=EN-US>3</font></p></div></body>
<!-- EDGAR Validation Code: 2E64D774 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<head> <title> Exhibit 99.1 </title> </head> <body vlink=#954f72 link=#0071bb lang=EN-US> <div class=WordSection1> <p class=MsoNormal style="MARGIN-BOTTOM:12pt; LINE-HEIGHT:normal"><font style='FONT-SIZE:11.5pt; FONT-FAMILY:"Open Sans","sans-serif"; COLOR:#0067b1'></font><b><font style="FONT-SIZE:16.5pt; FONT-FAMILY:Avenir; COLOR:#002c40"><img width=726 height=123 style="HEIGHT:60px; WIDTH:300px" src=graphic1.jpg>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NEWS</font></b></p> <p class=MsoNormal style="MARGIN-BOTTOM:0pt; TEXT-ALIGN:center; LINE-HEIGHT:normal" align=center><b><font style='FONT-SIZE:14pt; FONT-FAMILY:"Arial","sans-serif"'>Biomerica Signs Exclusive Distribution Agreement in Canada for its New and Proprietary <i>Helicobacter Pylori</i> (<i>H. pylori</i>) Test, hp+detect</font></b>&#153;<b><font style='FONT-SIZE:14pt; FONT-FAMILY:"Arial","sans-serif"'> </font></b></p> <p class=MsoListParagraph style="MARGIN-LEFT:0.75in; TEXT-INDENT:-0.25in"><font style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; LINE-HEIGHT:107%'>-<font style='FONT:7pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></font><b><font style='FONT-SIZE:12pt; FONT-FAMILY:"Arial","sans-serif"; LINE-HEIGHT:107%'>Prevalence of <i>H. Pylori</i> infection in the United States is approximately 35% to 40% of the population</font></b></p> <p class=MsoNormal style="MARGIN-BOTTOM:0pt; LINE-HEIGHT:normal" align=justify><font style='FONT-FAMILY:"Arial","sans-serif"' lang=ES>IRVINE, CA--(June 24, 2021) - Biomerica Inc. </font><font style='FONT-FAMILY:"Arial","sans-serif"'>(NASDAQ: </font><font style='FONT-FAMILY:"Arial","sans-serif"; COLOR:windowtext'>BMRA</font></a><font style='FONT-FAMILY:"Arial","sans-serif"'>) today announced that it has signed an exclusive five-year distribution agreement with a Canadian partner for the distribution and marketing of Biomerica&#146;s new and proprietary <i>Helicobacter pylori</i> test, called hp+detect</font>&#153;<font style='FONT-FAMILY:"Arial","sans-serif"'>.&nbsp; The hp+detect</font>&#153;<font style='FONT-FAMILY:"Arial","sans-serif"'> product has been developed for the identification and monitoring of <i>H. pylori </i>infection, the leading cause of duodenal and gastric ulcers, and a contributing risk factor associated with gastric cancer. Physicians and medical centers can use hp+detect</font>&#153;<font style='FONT-FAMILY:"Arial","sans-serif"'> to diagnose the presence of <i>H. pylori</i> and to monitor the efficacy of treatment.</font></p> <p style="MARGIN-BOTTOM:0pt; LINE-HEIGHT:normal" align=justify><font style='FONT-FAMILY:"Arial","sans-serif"'>In order to sell the product in Canada, Biomerica&#146;s distribution partner will now seek Health Canada clearance using the clinical data recently generated by Biomerica using the hp+detect&#153; product. The Company also intends to seek a CE Mark for the product to be sold in the European Union and FDA clearance in the USA.</font></p> <p class=MsoNormal style="MARGIN-BOTTOM:0pt; LINE-HEIGHT:normal" align=justify><font style='FONT-FAMILY:"Arial","sans-serif"'>Biomerica&#146;s test is designed to increase the sensitivity and specificity of <i>H. pylori</i> testing as compared to certain other products currently in the market.</font></p> <p class=MsoNormal style="MARGIN-BOTTOM:0pt; LINE-HEIGHT:normal" align=justify><font style='FONT-FAMILY:"Arial","sans-serif"'>According to the U.S. Center for Disease Control and Prevention, &#147;The prevalence of&nbsp;<i>Helicobacter pylori</i>&nbsp;infection worldwide is approximately 50%, and as high as 80%&#150;90% in developing countries, and &#8776;35%&#150;40% in the United States. Approximately 20% of persons infected with&nbsp;<i>H. pylori</i>&nbsp;develop related gastroduodenal disorders during their lifetime.&#148;<sup>1</sup> </font></p> <p class=MsoNormal style="MARGIN-BOTTOM:0pt; LINE-HEIGHT:normal" align=justify><font style='FONT-FAMILY:"Arial","sans-serif"'>&#147;<i>H. pylori </i>infection can cause serious health conditions, so early detection of the disease in symptomatic patients is important for those infected with these bacteria. &nbsp;&nbsp;Our </font><font style='FONT-FAMILY:"Arial","sans-serif"'>hp+detect</font>&#153;<font style='FONT-FAMILY:"Arial","sans-serif"'> </font><font style='FONT-FAMILY:"Arial","sans-serif"'>product identifies the presence of <i>H. pylori</i> antigen, enabling doctors to diagnose patients, as well as monitor treatment efficacy. Because of the rise of antibiotic resistance in <i>H. pylori</i> treatment, and the long-term cancer risk associated with proton-pump inhibitor ulcer medication use, it is important to monitor the eradication of infection,&#148; said Zack Irani, Chairman and Chief Executive Officer of Biomerica. &#147;We&#146;re pleased to enter into this relationship with a well-established medical distributor in Canada. This partnership will be our first step to launching the hp+detect</font>&#153;<font style='FONT-FAMILY:"Arial","sans-serif"'> test in markets around the world to assist gastroenterologists and other medical professionals who are dedicated to preventing ulcers and gastric cancer in the patients they treat.&#148; </font></p> <p align=justify><strong><font style='FONT-SIZE:11pt; FONT-FAMILY:"Arial","sans-serif"'>About Biomerica (NASDAQ: BMRA)</font></strong><font style='FONT-SIZE:11pt; FONT-FAMILY:"Arial","sans-serif"'><br>Biomerica, Inc. (</font><font style='FONT-SIZE:11pt; FONT-FAMILY:"Arial","sans-serif"; COLOR:windowtext'>www.biomerica.com</font><font style='FONT-SIZE:11pt; FONT-FAMILY:"Arial","sans-serif"'>) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point of care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica&#146;s primarily focus is on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.</font></p> <hr> <DIV style="PAGE-BREAK-BEFORE: always">&nbsp;</DIV> <p align=justify><strong><font style='FONT-SIZE:11pt; FONT-FAMILY:"Arial","sans-serif"'>About InFoods<sup>&#174;</sup></font></strong><font style='FONT-SIZE:11pt; FONT-FAMILY:"Arial","sans-serif"'><br>The Biomerica InFoods<sup>&#174;</sup>&nbsp;IBS product is designed to allow physicians to identify patient-specific foods (e.g., eggs, broccoli, wheat, potatoes, pork, etc.), that when removed from the diet, may alleviate or improve an individual's IBS symptoms including, but not limited to, constipation, diarrhea, bloating, pain and indigestion. This patented, diagnostic-guided therapy is designed to allow for a patient-specific, guided dietary regimen to improve Irritable Bowel Syndrome &#147;(IBS&#148;) outcomes. A point-of-care version of the product is being developed to allow physicians to perform the test in-office using a finger stick blood sample, while a clinical lab version of the product is expected to be the first for which the Company will seek regulatory approval. A billable CPT code that can be used by both clinical labs and physicians' offices is already available for InFoods<sup>&#174;</sup>&nbsp;products. Since the InFoods<sup>&#174;</sup>&nbsp;product is a diagnostic-guided therapy, and not a drug, it has no drug type side effects. An estimated 45 million people in America currently suffer from IBS, making it a leading cause for patient doctor visits.</font></p> <p class=MsoNormal><font style='FONT-SIZE:9pt; FONT-FAMILY:"Arial","sans-serif"; LINE-HEIGHT:107%'>1.</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Arial","sans-serif"; LINE-HEIGHT:107%'>&nbsp; </font><font style='FONT-SIZE:10pt; FONT-FAMILY:"Helvetica Neue"; BACKGROUND:white; COLOR:#0a0a0a; LINE-HEIGHT:107%'>Duck WM, Sobel J, Pruckler JM, et al. Antimicrobial Resistance Incidence and Risk Factors among Helicobacter pylori&#150;Infected Persons, United States.&nbsp;</font><i><font style='FONT-SIZE:10pt; FONT-FAMILY:"Helvetica Neue"; COLOR:#0a0a0a; LINE-HEIGHT:107%'>Emerging Infectious Diseases</font></i><font style='FONT-SIZE:10pt; FONT-FAMILY:"Helvetica Neue"; BACKGROUND:white; COLOR:#0a0a0a; LINE-HEIGHT:107%'>. 2004;10(6):1088-1094. doi:10.3201/eid1006.030744.</font><font style='FONT-SIZE:9pt; FONT-FAMILY:"Arial","sans-serif"; LINE-HEIGHT:107%'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p> <p align=justify><font style='FONT-SIZE:10pt; FONT-FAMILY:"Arial","sans-serif"'>The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to the efficacy of the Company&#146;s H. pylori and other tests, FDA clearance of the Company&#146;s products including the hp-detect product, Health Canada and CE Mark clearance of these products, the rapidity of testing results, uniqueness of the Company&#146;s products, test result accuracy of products, pricing of the Company&#146;s test kits, demand for domestic or international orders, potential revenues from the sale of current or future products, availability of the Company&#146;s test kits, and patent protection on any of the Company&#146;s products or technologies. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, including, without limitation: results of studies testing the efficacy of the Company&#146;s tests, InFoods tests and other products; regulatory approvals necessary prior to commercialization of the Company&#146;s products; availability of the Company&#146;s test kits and other products; capacity, resource and other constraints on our suppliers; dependence on our third party manufacturers; dependence on international shipping carriers; governmental import/export regulations; demand for our various tests and other products; competition from other similar products and from competitors that have significantly more financial and other resources available to them; governmental virus control regulations that make it difficult or impossible for the company to maintain current operations; regulations and the Company&#146;s ability to obtain patent protection on any aspects of its rapid test technologies. Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Additionally, potential risks and uncertainties include, among others, fluctuations in the Company's operating results due to its business model and expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company's dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.</font></p> <p><font style='FONT-SIZE:11pt; FONT-FAMILY:"Arial","sans-serif"'>Corporate Contact:</font></p> <p><font style='FONT-SIZE:11pt; FONT-FAMILY:"Arial","sans-serif"'>John Nesbett /Jennifer Belodeau<br>IMS Investor Relations<br>203.972.9200<br></font><font style='FONT-SIZE:11pt; FONT-FAMILY:"Arial","sans-serif"; COLOR:windowtext'>jnesbett@institutionalms.com</font></p> <p><font class=MsoHyperlink><font style='FONT-SIZE:11pt; FONT-FAMILY:"Arial","sans-serif"; COLOR:windowtext'></font></font>&nbsp;</p> <p><font style='FONT-SIZE:11pt; FONT-FAMILY:"Arial","sans-serif"'>Source: Biomerica, Inc.</font></p></div></body>
<!-- EDGAR Validation Code: 1935F42B -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>graphic1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 graphic1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ![ M<# 2(  A$! Q$!_\0
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MD?33(/RJ3_A7F@?] V'\J^$_UKI_\^S[G_56K_S\/R!O9?$NC?\ 'Q)?Q?\
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MVFL,OW=,_(9NO_$9ZM^SS\2M6T?XF:5Y]_/+;22?O/,DK]6-/O(]2L8KA/\
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M^Z:6DKC/0/RR_; OX[KXF7$"?ZSS*\%6W+-C/%?I3\3?V.=,^(/BBXU:>?\
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MG+<A7UG,*G/,Y666263S)/WM1^77T3X/_8[\7:Q)&]Y:BUC^M>]^#?V&-$M
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MG[EL*V;?X!^!(_NZ%C_M\N/_ (Y5RW^#?A"'[FDLO_;W/_\ %TN5H%4R>/\
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LJ:BBH,!*6BB@!*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
